Zacks Investment Research cut shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) from a hold rating to a sell rating in a research note published on Friday, May 12th.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 3.92% during trading on Friday, hitting $33.94. The stock had a trading volume of 600,930 shares. Enanta Pharmaceuticals has a 52-week low of $20.79 and a 52-week high of $37.31. The company’s market cap is $647.68 million. The firm’s 50-day moving average price is $31.52 and its 200-day moving average price is $31.40.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.10. Enanta Pharmaceuticals had a negative net margin of 28.68% and a negative return on equity of 4.94%. The business had revenue of $9 million during the quarter, compared to analysts’ expectations of $9.19 million. During the same period last year, the company posted ($0.09) EPS. The company’s revenue was down 30.8% on a year-over-year basis. Analysts predict that Enanta Pharmaceuticals will post ($0.05) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Mason Street Advisors LLC boosted its position in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the period. WFG Advisors LP raised its stake in shares of Enanta Pharmaceuticals by 3,243.2% in the fourth quarter. WFG Advisors LP now owns 1,471 shares of the biotechnology company’s stock worth $109,000 after buying an additional 1,427 shares during the period. State Board of Administration of Florida Retirement System purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $204,000. Glassman Wealth Services purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $223,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $234,000. 67.57% of the stock is owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Enanta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc. and related companies.